Federal Circuit invalidates Nuvo’s Vimovo patents

17-05-2019

Federal Circuit invalidates Nuvo’s Vimovo patents

Duncan_Andison / iStockphoto.com

The US Court of Appeals for the Federal Circuit has delivered a blow to Nuvo Pharmaceuticals by reversing a decision which had upheld the validity of the Canadian company’s pain relief drug Vimovo (naproxen/esomeprazole magnesium).


US Court of Appeals for the Federal Circuit, Horizon Pharma, Nuvo Pharmaceuticals, Vimovo, patent invalidity, arthritis, generic competition

LSIPR